Furthermore, studies suggest that EGFR mutations play a pivotal role in the evolution of lung adenocarcinoma, enhancing the tumor’s ability to adapt to existing therapies and leading to diminished therapeutic efficacy and the development of resistance (33, 34). This evidence concerns the gene EGFR and lung adenocarcinoma.